Background
TNBC
TRIPLE-NEGATIVE BREAST CANCER
The undetermined efficacy of the current standard-of-care neoadjuvant treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple-negative breast cancer (TNBC) and germline 